Aethlon Medical Inc AEMD
We take great care to ensure that the data presented and summarized in this overview for AETHLON MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AEMD
Top Purchases
Top Sells
About AEMD
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Insider Transactions at AEMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Chetan Shah Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,786
-8.2%
|
$1,786
$1.2 P/Share
|
|
Jun 30
2025
|
Nicolas Gikakis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,786
-8.2%
|
$1,786
$1.2 P/Share
|
|
Jun 30
2025
|
Edward G Broenniman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-3.93%
|
$893
$1.2 P/Share
|
|
Apr 23
2025
|
Chetan Shah Director |
SELL
Grant, award, or other acquisition
|
Direct |
142,857
-45.05%
|
$0
$0.36 P/Share
|
|
Apr 23
2025
|
Edward G Broenniman Director |
BUY
Grant, award, or other acquisition
|
Direct |
142,857
+44.01%
|
$0
$0.35 P/Share
|
|
Apr 23
2025
|
Angela Rossetti Director |
BUY
Grant, award, or other acquisition
|
Direct |
142,857
+29.38%
|
$0
$0.35 P/Share
|
|
Apr 23
2025
|
Nicolas Gikakis Director |
BUY
Grant, award, or other acquisition
|
Direct |
142,857
+45.04%
|
$0
$0.35 P/Share
|
|
Mar 31
2025
|
Nicolas Gikakis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-9.46%
|
$0
$0.36 P/Share
|
|
Mar 31
2025
|
Chetan Shah Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-9.49%
|
$0
$0.36 P/Share
|
|
Mar 31
2025
|
Edward G Broenniman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,645
-4.06%
|
$0
$0.36 P/Share
|
|
Dec 31
2024
|
Nicolas Gikakis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-8.65%
|
$0
$0.86 P/Share
|
|
Dec 31
2024
|
Chetan Shah Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-8.67%
|
$0
$0.86 P/Share
|
|
Dec 31
2024
|
Edward G Broenniman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,645
-3.9%
|
$0
$0.86 P/Share
|
|
Sep 30
2024
|
Chetan Shah Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-7.97%
|
$0
$0.47 P/Share
|
|
Sep 30
2024
|
Edward G Broenniman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,645
-3.75%
|
$0
$0.47 P/Share
|
|
Sep 30
2024
|
Nicolas Gikakis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-7.96%
|
$0
$0.47 P/Share
|
|
Jun 28
2024
|
Edward G Broenniman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,645
-3.62%
|
$0
$0.5 P/Share
|
|
Jun 28
2024
|
Nicolas Gikakis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,244
-11.26%
|
$0
$0.5 P/Share
|
|
Jun 28
2024
|
Chetan Shah Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,289
-7.39%
|
$0
$0.5 P/Share
|
|
Apr 16
2024
|
Edward G Broenniman Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,894
+41.98%
|
$32,894
$1.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 429K shares |
|---|
| Grant, award, or other acquisition | 143K shares |
|---|---|
| Payment of exercise price or tax liability | 29.1K shares |